Coherus Oncology (CHRS) Preferred Stock Liabilities (2013 - 2014)
Coherus Oncology (CHRS) recorded Preferred Stock Liabilities of $161.16 million in Q3 2014.
Powered by 
Analysis
Coherus Oncology (CHRS) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
At the end of FY2013, Coherus Oncology reported Preferred Stock Liabilities of $54.7 million, up 993.9% from FY2012.
- Across earlier years, Preferred Stock Liabilities came in at $5 million in FY2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,221.54 Bn | 1,195.15 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 650.21 Bn | 570.07 Bn | 17.30 Bn | - |
| 3 | AbbVie | 508.24 Bn | 476.24 Bn | 13.12 Bn | - |
| 4 | Merck | 360.07 Bn | 323.01 Bn | 13.19 Bn | - |
| 5 | Novartis Ag | 312.26 Bn | 285.49 Bn | - | - |
| 6 | Astrazeneca | 285.31 Bn | 259.20 Bn | 13.26 Bn | - |
| 7 | Amgen | 247.74 Bn | 199.39 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 207.12 Bn | 182.22 Bn | 6.73 Bn | - |
| 9 | Pfizer | 166.13 Bn | 113.48 Bn | 12.56 Bn | - |
| 10 | Coherus Oncology | 116.17 Mn | -519.97 Mn | 10.07 Mn | - |
API Access
Coherus Oncology Preferred Stock Liabilities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=CHRS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "preferred-stock-liabilities", "ticker": "CHRS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=CHRS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();